Effects of pentoxifylline on non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial in Iran

Hepatitis Monthly

Volumn 15, Issue 11, 2015, Pages

  Baniasadi, Nadieh ^a   Salajegheh, Faranak ^b   Pardakhty, Abbas ^c   Seyedmirzaee, Seyed Mehdi ^b   Hayatbakhsh, Mohammad Mahdi ^d   Nikpoor, Amin Reza ^e   Mohammadi, Mojgan ^e,f  

^a BAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical trial; Cytokines; Non alcoholic fatty liver disease; Pentoxifylline

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 6; INTERLEUKIN 8; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IRAN; MALE; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL;

EID: 84990308922     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.32418     Document Type: Article

References (30)

1. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33(5):525–40. doi: 10.1111/j.1365-2036.2010.04556.x. [PubMed: 21198708]
2. Peverill W, Powell LW, Skoien R. Evolving concepts in the patho­genesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15(5):8591–638. doi: 10.3390/ijms15058591. [PubMed: 24830559]
3. Choi S, Diehl AM. Role of inflammation in nonalcoholic steato­hepatitis. Curr Opin Gastroenterol. 2005;21(6):702–7. [PubMed: 16220049]
4. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191(2):235–40. doi: 10.1016/j.atherosclerosis.2006.08.021. [PubMed: 16970951]
5. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409–15. doi: 10.1172/JCI117936. [PubMed: 7738205]
6. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245(6):621–5. [PubMed: 10395191]
7. Muriel P, Fernandez-Martinez E, Perez-Alvarez V, Lara-Ochoa F, Ponce S, Garcia J, et al. Thalidomide ameliorates carbon tetra­chloride induced cirrhosis in the rat. Eur J Gastroenterol Hepa­tol. 2003;15(9):951–7. doi: 10.1097/01.meg.0000059201.12802.ef. [PubMed: 12923366]
8. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic ste­atohepatitis. N Engl J Med. 2000;343(20):1467–76. doi: 10.1056/NEJM200011163432007. [PubMed: 11078773]
9. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninva­sive strategy. JAMA. 2001;286(17):2107–13. [PubMed: 11694151]
10. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Mo­lecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14(2):72–81. doi: 10.1016/j.molmed.2007.12.003. [PubMed: 18218340]
11. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 2003;27 Suppl 3:S6–11. doi: 10.1038/sj.ijo.0802491. [PubMed: 14704736]
12. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resis­tance. J Clin Invest. 2006;116(7):1793–801. doi: 10.1172/JCI29069. [PubMed: 16823477]
13. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27(5):412–21. doi: 10.1111/j.1365-2036.2007.03586.x. [PubMed: 18081738]
14. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pent­oxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol. 2004;41(4):592–8. doi: 10.1016/j.jhep.2004.06.030. [PubMed: 15464239]
15. Hernandez E, Correa A, Bucio L, Souza V, Kershenobich D, Gutierrez-Ruiz MC. Pentoxifylline diminished acetaldehyde-induced colla­gen production in hepatic stellate cells by decreasing interleukin-6 expression. Pharmacol Res. 2002;46(5):435–43. [PubMed: 12419648]
16. Balibrea JL, Arias-Diaz J, Garcia C, Vara E. Effect of pentoxifyl­line and somatostatin on tumour necrosis factor production by human pulmonary macrophages. Circ Shock. 1994;43(2):51–6. [PubMed: 7834820]
17. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, et al. A ran­domized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int. 2008;2(2):196–201. doi: 10.1007/s12072-008-9058-1. [PubMed: 19669304]
18. Tuncer İ, Uygan İ, Dülger H, Türkdoğan K, Şekeroğlu MR, Kösem M. The comparative effects of pentoxifylline and ursodeoxycho­lic acid on IL-1β, Il-6, Il-8 and TNF-α levels in nonalcoholic fatty liver. Eastyern J Med. 2003;8:27–32.
19. Georgescu EF, Georgescu M. Therapeutic options in non-alco­holic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007;16(1):39–46. [PubMed: 17410287]
20. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pent­oxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99(12):2365–8. doi: 10.1111/j.1572-0241.2004.40064.x. [PubMed: 15571584]
21. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Ben­eficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepa­titis. J Gastroenterol Hepatol. 2007;22(5):634–8. doi: 10.1111/j.1440-1746.2006.04756.x. [PubMed: 17444848]
22. Brunt EM, editor. Nonalcoholic steatohepatitis: pathologic fea­tures and differential diagnosis.; Seminars in diagnostic pathol­ogy.; 2005; Elsevier;330–8.
23. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 2007;128(5):837–47. doi: 10.1309/RTPM1PY6YG­BL2G2R. [PubMed: 17951208]
24. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pent­oxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterol­ogy. 2000;119(6):1637–48. [PubMed: 11113085]
25. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011;10(3):277–86. [PubMed: 21677329]
26. Buranawui W, Thung-u-thaisri P, Pramoolsinsap C. Pentoxifylline for treatment of non-alcoholic fatty liver disease (NAFLD): a ran­domized, placebo-controlled study [Abstract s2161]. Gastroenter­ology A. 2006;330.
27. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a ran­domized placebo-controlled trial. Hepatology. 2011;54(5):1610–9. doi: 10.1002/hep.24544. [PubMed: 21748765]
28. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcohol­ic fatty liver disease. Lipids Health Dis. 2011;10:49. doi: 10.1186/1476-511X-10-49. [PubMed: 21477300]
29. Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonal­coholic fatty liver disease: a meta-analysis. World J Gastroen­terol. 2014;20(2):569–77. doi: 10.3748/wjg.v20.i2.569. [PubMed: 24574727]
30. Jamali R, Dowlatshahi S, Hajatian M. The effect of Pentoxifylline on Liver function tests in Non-alcoholic Fatty Liver Disease Non-diabetic Patients. Govaresh. 2015;20(2):90–6.